Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Feng

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
JAMA Oncology|March 14, 2024
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical TrialMark K Buyyounouski, Stephanie L Pugh, Ronald C Chen, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent CancersYaru Xu, Zhaoning Wang, Martin Sjöström, et al.
Head & Neck|April 19, 2013
Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynxIrina Y Dobrosotskaya, Emily Bellile, Matthew E Spector, et al.
Lancet (London, England)|May 15, 2022
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trialAlan Pollack, Theodore G Karrison, Alexander G Balogh, et al.
European Urology Oncology|February 19, 2021
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional ImagingTing Martin Ma, Andrei Gafita, David Shabsovich, et al.
Communications Medicine|August 21, 2025
Leveraging sequences missing from the human genome to diagnose cancerIlias Georgakopoulos-Soares, Ofer Yizhar-Barnea, Ioannis Mouratidis, et al.
Advances in Radiation Oncology|May 27, 2024
Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate CancerPhilip Sutera, Matthew P Deek, Rebecca A Deek, et al.
JCO Clinical Cancer Informatics|July 1, 2022
Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415Rahul Khairnar, Lyudmila DeMora, Howard M Sandler, et al.
European Urology|December 11, 2020
Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate CancerKosj Yamoah, Shivanshu Awasthi, Brandon A Mahal, et al.
Nature Cancer|July 14, 2021
Accelerating precision medicine in metastatic prostate cancerJoaquin Mateo, Rana McKay, Wassim Abida, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
JAMA Oncology|March 14, 2024
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical TrialMark K Buyyounouski, Stephanie L Pugh, Ronald C Chen, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent CancersYaru Xu, Zhaoning Wang, Martin Sjöström, et al.
Head & Neck|April 19, 2013
Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynxIrina Y Dobrosotskaya, Emily Bellile, Matthew E Spector, et al.
Lancet (London, England)|May 15, 2022
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trialAlan Pollack, Theodore G Karrison, Alexander G Balogh, et al.
European Urology Oncology|February 19, 2021
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional ImagingTing Martin Ma, Andrei Gafita, David Shabsovich, et al.
Communications Medicine|August 21, 2025
Leveraging sequences missing from the human genome to diagnose cancerIlias Georgakopoulos-Soares, Ofer Yizhar-Barnea, Ioannis Mouratidis, et al.
Advances in Radiation Oncology|May 27, 2024
Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate CancerPhilip Sutera, Matthew P Deek, Rebecca A Deek, et al.
JCO Clinical Cancer Informatics|July 1, 2022
Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415Rahul Khairnar, Lyudmila DeMora, Howard M Sandler, et al.
European Urology|December 11, 2020
Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate CancerKosj Yamoah, Shivanshu Awasthi, Brandon A Mahal, et al.
Nature Cancer|July 14, 2021
Accelerating precision medicine in metastatic prostate cancerJoaquin Mateo, Rana McKay, Wassim Abida, et al.
Pageof 8